Patient Support Hotline

Call (844) 244-1309

ZERO360 is a free, comprehensive patient support service to help patients and their families navigate insurance and financial obstacles to cover treatment and other critical needs associated with cancer.


Subscribe to our E-Newsletter

Stay up-to-date on the latest news about prostate cancer. Join our distribution list to receive periodic email updates and our monthly e-newsletter.

  • Patient Support (844) 244-1309
  • Search
  • e-News Signup Enews Signup
  • Run/Walk
  • Donate

- test

Genentech’s IPATential150 Study Evaluating Ipatasertib in Combination With Abiraterone and Prednisone/Prednisolone Met One of Its Co-Primary Endpoints

Phase III IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone compared to current standard-of-care (abiraterone and prednisone/prednisolone alone)... Read More

LYNPARZA® (olaparib) demonstrated overall survival benefit in Phase III PROfound trial for BRCA 1/2 or ATM-mutated metastatic castration-resistant prostate cancer

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced further positive results from... Read More

Bayer’s Prostate Cancer Drug Earns FDA Approval

The U.S. Food and Drug Administration (FDA) approved Bayer’s Nubeqa (darolutamide) for non-metastatic castration-resistant prostate cancer (nmCRPC). The clinical trial evaluated Nubeqa (an... Read More

Treatment Outcome Data From The Prostate Cancer Registry Presented For The First Time At The 2016 European Society For Medical Oncology (ESMO) Congress

Janssen-Cilag International NV presented the first reported primary treatment outcome data from The Prostate Cancer Registry, Europe’s first and largest... Read More

Nymox (NYMX)’s New Phase III Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show

Nymox Pharmaceutical Corporation (Nasdaq:NYMX) lead drug fexapotide, which has been in development for over a decade, and which has been... Read More